A Canadian-based blog featuring insiders' perspectives on the world of stem cells and regenerative medicine. Published by CCRM.
Toronto, Ontario
Joined May 2018
- Tweets3K
- Following348
- Followers574
- Likes1.7K
Signals retweeted
Researchers are learning to crack the blood-brain barrier to get drugs more easily into the brain. This has opened doors for treating a rare genetic disorder and is being tested in Phase 3 trials for Alzheimer's.
My latest in @NatGeo: nationalgeographic.com/healt…
Signals retweeted
Don't forget to vote for the #CellsISee People's Choice Award by October 7, 2026. #Sciart #contest hosted by CCRM and @StemCellNetwork
Vote here: facebook.com/media/set/?set=…
Signals retweeted
A fifth cell and gene therapy product has been approved in the US this year.
Today, the FDA announced approval of an AAV gene therapy developed by ARM member Ultragenyx to treat pediatric patients with Sanfilippo syndrome Type A. 1/2
fda.gov/news-events/press-an…
Signals retweeted
Banner week for #DeepTechBioLab: 1st a workshop at @IEEEQuantumWeek & then an event in the @biolabs @UofT space, with presentations & a panel. Want to learn more how we are bringing together #DeepTech companies with #lifesciences? ccrm.ca/deeptech-bio-lab/ @IonQ_Inc @KausarSamli
Signals retweeted
ICYMI: my call for Japan to do more to stop its huge & growing unproven stem cell/regenerative clinic industry after some deaths and many adverse events ipscell.com/2026/09/amid-pat… @ISSCR @ISCTglobal @CaulfieldTim @Signalsblogs
Signals retweeted
How do we make CGTs more accessible to patients globally? In the new episode of our podcast, @bambi_grilley & #StaciArnold explore manufacturing & delivery challenges, regulation, P3s & more. Listen where you stream podcasts or at ccrm.ca/podcast. @KristaLambComms
Signals retweeted
The 2026 #CellsISee People’s Choice Award voting is now open! "Like" your favourite and the lucky winner will receive $500 at #TMM2026. The #sciart #contest is co-hosted with @StemCellNetwork Vote here: facebook.com/media/set/?vani… Pls RT
Signals retweeted
🤩 Hope you're excited for our next guest, Dr. Yonatan Stelzer at @WeizmannScience!
The Stelzer Lab investigates how cell fate and identity are established during #embryonic development using single-cell and epigenomic approaches. 🧫
Check out his latest work: bit.ly/3UsGAsB
Signals retweeted
Inspiring Canada’s next generation of thinkers and problem-solvers starts with empowering educators! Our expanded free, bilingual STEM programming suite gives teachers even more turnkey, Canadian-context tools to bring into their classrooms. Read more:bit.ly/3V0CjaZ
Signals retweeted
Scientists stress-tested genes across 22 million human immune cells—using real cells from real donors, not lab models.
Emma Dann & Ronghui Zhu break down why this massive new dataset could reshape cancer immunotherapy and autoimmune treatment.
bit.ly/4xhJxKi
Signals retweeted
The 2026 Cells I See art contest closes today – Fri., Sept. 4! Enter your #sciart now for the chance to win cash prizes. Head to the website for full contest rules, submission instructions and to view past submissions cellsisee.ccrm.ca/ Pls RT!
Signals retweeted
Dr. Lisa Barrett, Professor in the Department of Medicine at Dalhousie University, calls for a bolder immunization future.
The goal is bigger than avoiding infection. It is giving people the freedom to work, learn, create, and live without being derailed by preventable disease.
That vision is explored by Dr. Barrett alongside Wendy Zatylny, President & CEO of BIOTECanada, with David D. Jones, Managing Director of Merck Canada, guiding the discussion.
Featured in The Future of Life Sciences Expert Series, presented by Merck Canada.
Signals retweeted
After battling leukemia and receiving a stem cell transplant, Liam knows firsthand the impact a donor can have. 🧡
Now a Gift of Life Campus Ambassador at Clemson University, Liam shares his experience at the 2026 Campus Ambassador Retreat.
#CureBloodCancer #YouCure
Signals retweeted
What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04wthsD0
>Ocugen announced that it has dosed the first patient in its global Phase III trial for OCU410
> Genprex has partnered with Andelyn Biosciences to advance its diabetes gene therapy program
> Complement Therapeutics has completed its Phase I/II cohort 2 dosing of its gene therapy for geographic atrophy
Signals retweeted
Celebrating 20 years of iPS cells with a $200 contest ipscell.com/2026/09/celebrat… Please RT #stemcells #stemcells
Signals retweeted
Every three minutes, someone in the U.S. is diagnosed with blood cancer.
When Lori needed a transplant to treat AML, Adam was her matching stem cell donor. He had joined the registry with a simple cheek swab.
This #BloodCancerAwarenessMonth, join at giftoflife.org. 🧡
Signals retweeted
🔔 The next episode has dropped!
Dr. Charles Easley at @uga_ehs discusses how his lab uses #PSCs and in vitro models of #spermatogenesis to investigate how environmental exposures affect male fertility.
Tune in now! bit.ly/4wV6VNv
Signals retweeted
Canada has invested heavily in #biomanufacturing infrastructure. Now, we need to ensure it’s being put to work. CCRM & #OmniaBio are helping #biotech companies move from innovation to clinical manufacturing with commercial scale in mind from day one. hospitalnews.com/canada-need…
Signals retweeted
#CMC isn’t just a regulatory requirement. In the latest episode of our podcast, @katyspinkdhcg & Craig Beasley discuss how a strong CMC strategy can cut risk, support commercialization & create value for CGT companies. Listen where you stream podcasts or ccrm.ca/podcast
Signals retweeted
There are only two weeks left to submit entries to the 2026 Cells I See #sciart #contest for the chance to win cash prizes. Head to the website for full contest rules, submission instructions and to view past submissions cellsisee.ccrm.ca/ @StemCellNetwork
